Carlisle Companies Incorporated (CSL) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Carlisle Companies Incorporated  (NYSE: CSL)


Carlisle Companies Incorporated's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Carlisle Companies Incorporated's ROI in the third quarter of 2026?
Carlisle Companies Incorporated achieved a return on average invested assets (ROI) of 14.57 % in its third quarter of 2026, this is above CSL's average return on investment of 11.88%.
Carlisle Companies Incorporateds investments during the 12 months ending in the third quarter of 2026 are valued at $4 billion

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 61 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 226, from total ROI ranking in the second quarter of 2026 at 232.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 14.05 % 13.86 % 0.82 % -5.48 % -12.73 %
Y / Y Net Income Change TTM -7.43 % -10.13 % 31.74 % 81.95 % 217.68 %
Investment (TTM) in Millions 5,155 5,351 4,537 4,677 4,871
Return On Investment (TTM) 14.57 % 14.91 % 16.03 % 16.82 % 17.95 %
CSL's Overall Ranking # 226 # 232 # 67 # 53 #
Seq. Investment Change TTM 1.46 % 7.4 % 2.72 % 1.89 % 1.29 %
Seq. Net Income Change TTM -0.84 % -0.08 % -2.11 % -4.56 % -3.73 %
Net Income (TTM) in Millions 718 725 725 741 776




Return On Investment CSL's Ranking
Within: No.
Industry # 12
Sector # 62
Overall # 226

Return On Investment Statistics
High Average Low
29.62 %
11.88 %
5.93 %
  (Mar 31 2021)







Financial Statements
Carlisle Companies Incorporated's III. Quarter Investments $ 5,155 Millions CSL's Balance sheet
Carlisle Companies Incorporated's III. Quarter Income $ 208 Millions Quarterly CSL's Income Statement
CSL's Income by Division See CSL's Income by Division


CSL Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 4,677 4,351 5,525 5,306 5,827
Y / Y Investment Growth 7.5 % -21.25 % 4.12 % -8.95 % 16.91 %
Net Income in Millions 741 1,312 766 924 422
Y / Y Net Income Growth -43.54 % 71.34 % -17.14 % 119.11 % 31.74 %
Annual Return On Investment 15.84 % 30.15 % 13.86 % 17.41 % 7.24 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 15.84 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CSL's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CSL's Competitors
Subscribers only: Roi for Carlisle Companies Incorporated's Suppliers
Subscribers only: Return On Investment for CSL's Customers

Other Ratios
CSL's Roa CSL's Inventory Turnover Ratio CSL's Growth Rates CSL's Dividend Statistics
CSL's Profitability Ratios CSL's Asset Turnover Ratio CSL's Dividend Growth
CSL's Roe CSL's Valuation Ratios CSL's Financial Strength Ratios CSL's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %


Date modified: 2026-10-30T16:59:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.